Gregory W Albers, MD
Neurology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Albers’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G55661 · Current
Licensed to practise in California · since 1985 · expires 2027-03-31 · University of California, San Diego School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$11,176
Medicare paid this office $11,176 for 62 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $2,553 | $106 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $2,489 | $146 |
| Long return visit (40+ min) | 14 | $1,831 | $131 |
| New patient visit (60+ min) | 12 | $1,468 | $122 |
Who their Medicare patients are
62 Original Medicare patients in 2024. Average age 78 · Women 60% · Also on Medicaid 27% · Health risk score 2.18. Above the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 75% · Stroke 75% · Diabetes 48% · Coronary heart disease 47% · Chronic kidney disease 42% · Atrial fibrillation 39% · Depression 32% · Heart failure 29% · Dementia 23%.
The office billed $41,173, Medicare allowed $14,824 and paid $11,176; for 96 services of 10 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 62 | 96 | 78 | 2.18 | $41,173 | $11,176 |
| 2023 | 61 | 109 | 78 | 1.39 | $45,656 | $11,787 |
| 2021 | 72 | 120 | 77 | 1.97 | $45,475 | $11,492 |
| 2020 | 83 | 133 | 76 | 1.75 | $48,876 | $12,853 |
| 2019 | 77 | 130 | 77 | 1.81 | $40,706 | $11,282 |
| 2018 | 93 | 146 | 78 | 1.73 | $40,271 | $10,862 |
| 2017 | 71 | 121 | 75 | 1.68 | $37,125 | $9,754 |
| 2016 | 108 | 182 | 78 | 1.94 | $63,894 | $17,132 |
| 2015 | 93 | 168 | 78 | 1.75 | $60,913 | $16,964 |
| 2014 | 65 | 112 | 75 | 1.53 | $47,487 | $12,083 |
| 2013 | 120 | 235 | 76 | 1.61 | $102,217 | $24,438 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $2,554 | $73 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,281 | $152 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,554 | $120 |
| Long return visit (40+ min) | 11 | $1,463 | $133 |
2021: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $3,082 | $88 |
| Long return visit (40+ min) | 16 | $2,159 | $127 |
| Return visit (30+ min) | 12 | $699 | $58 |
2020: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $4,000 | $98 |
| New patient visit (45+ min) | 13 | $1,526 | $117 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,421 | $68 |
| Return visit (30+ min) | 14 | $897 | $64 |
2019: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 23 | $2,376 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $2,170 | $94 |
| Return visit (30+ min) | 12 | $933 | $67 |
| Hospital discharge day management, 30 minutes or less | 12 | $810 | $68 |
2018: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 34 | $3,726 | $65 |
| Return visit (30+ min) | 16 | $1,130 | $66 |
| Hospital discharge day management, 30 minutes or less | 12 | $735 | $61 |
2017: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $2,721 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,215 | $93 |
| Return visit (30+ min) | 11 | $846 | $65 |
2016: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $6,715 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,120 | $177 |
| New patient visit (45+ min) | 16 | $1,662 | $104 |
| Return visit (30+ min) | 19 | $1,336 | $67 |
| Hospital discharge day management, more than 30 minutes | 11 | $1,048 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $882 | $63 |
2015: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 36 | $6,996 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,538 | $181 |
| Hospital discharge day management, more than 30 minutes | 19 | $1,861 | $98 |
| New patient visit (45+ min) | 13 | $1,505 | $116 |
| Return visit (30+ min) | 13 | $984 | $70 |
2014: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $3,882 | $92 |
| Hospital discharge day management, more than 30 minutes | 11 | $1,062 | $97 |
| Return visit (30+ min) | 13 | $909 | $65 |
2013: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 47 | $10,189 | $90 |
| Critical care, first 30-74 minutes | 13 | $4,361 | $190 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,631 | $175 |
| New patient visit (45+ min) | 22 | $2,217 | $101 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,664 | $119 |
| Return visit (30+ min) | 17 | $1,227 | $58 |
Money from drug and device companies
$49,526 in 2025
| 2025 | 6 | 24 | $48,784 | $49,526 |
| 2024 | 3 | 18 | $54,548 | $62,037 |
| 2023 | 5 | 9 | $68,575 | $68,811 |
| 2022 | 1 | 12 | $40,000 | $40,000 |
| 2021 | 5 | 8 | $26,403 | $26,403 |
| 2020 | 4 | 7 | $46,525 | $46,797 |
| 2019 | 9 | 41 | $104,802 | $121,281 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| iSchemaView | None | $40,000 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | None | $7,392 | 7 payments
|
| Takeda Pharmaceuticals U.S.A. | None | $1,800 | 1 payment
|
| Ceribell | Pocket Eeg Device | $125 | 1 payment
|
| Boston Scientific | Overstitch Endoscopic Suturing System | $114 | 2 payments
|
| Celltrion USA | Zymfentra | $95 | 1 payment
|
See all 13 published payments
| Bayer Healthcare Pharmaceuticals | Consulting · 2025-09-04 | None | $2,328 |
| Takeda Pharmaceuticals U.S.A. | Consulting · 2025-07-03 | None | $1,800 |
| Ceribell | Meals · 2025-05-07 | Pocket Eeg Device | $125 |
| Celltrion USA | Meals · 2025-04-15 | Zymfentra | $95 |
| Boston Scientific | Meals · 2025-03-27 | Overstitch Endoscopic Suturing System | $65 |
| Boston Scientific | Meals · 2025-03-10 | Overstitch Endoscopic Suturing System | $49 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-02-06 | None | $150 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-02-03 | None | $48 |
| Bayer Healthcare Pharmaceuticals | Consulting · 2025-02-03 | None | $4,656 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-02-03 | None | $111 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-02-03 | None | $62 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-02-03 | None | $37 |
| iSchemaView | Consulting · 2025-01-15 | None | $40,000 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $62,037
| iSchemaView | None | $40,000 | 1 payment
|
| F. Hoffmann-La Roche AG | None | $17,837 | 5 payments
|
| CSL Behring | None | $4,200 | 1 payment
|
2023: $68,811
| iSchemaView | None | $40,000 | 1 payment
|
| Genentech | None | $23,400 | 2 payments
|
| Argenx US | None | $5,175 | 1 payment
|
| Nestle Healthcare Nutrition | Vowst | $125 | 1 payment
|
| Apollo Endosurgery US | Overstitch Endoscopic Suturing System | $111 | 1 payment
|
2022: $40,000
| iSchemaView | None | $40,000 | 1 payment
|
2021: $26,403
| Genentech | Activase | $13,440 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $3,953 | 2 payments
|
| Janssen Global Services | None | $3,750 | 1 payment
|
| Medtronic | None | $3,200 | 2 payments
|
| Daiichi Sankyo | Injectafer | $2,060 | 1 payment
|
2020: $46,797
| Genentech | Activase | $42,695 | 4 payments
|
| Janssen Research & Development | None | $4,000 | 1 payment
|
| American Regent | Injectafer | $59 | 1 payment
|
| Biogen | None | $43 | 1 payment
|
2019: $121,281
| Genentech | Activase | $83,600 | 9 payments
|
| AstraZeneca UK | None | $15,216 | 9 payments
|
| Portola Pharmaceuticals | Andexxa | $7,508 | 10 payments
|
| AstraZeneca AB | None | $6,402 | 2 payments
|
| Biogen | None | $3,675 | 1 payment
|
| Janssen Research & Development | Xarelto | $2,850 | 2 payments
|
| F. Hoffmann-La Roche AG | Activase | $1,767 | 4 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | None | $131 | 3 payments
|
| Genentech USA | Activase | $131 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Biogen, Inc. · Phase 3 Study To Evaluate the Efficacy and Safety of Intravenous Biib093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction · 2021 | This clinician | $2,850 |
| Biogen, Inc. · Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Intravenous Biib093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction · 2023 | This clinician | $1,187 |
| F. Hoffmann-La Roche AG · Tenecteplase in Stroke Patients Between 4 5 and 24 Hours · 2024 | This clinician | $1,103 |
| Biogen, Inc. · Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Intravenous Biib093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction · 2022 | This clinician | $950 |
| F. Hoffmann-La Roche AG · Efficacy and Safety of Tenecteplase in Patients With Late-Window Acute Ischaemic Stroke and Evidence of Salvageable Tissue: Results From the Phase III Timeless Trial · 2023 | This clinician | $687 |
| F. Hoffmann-La Roche AG · Efficacy and Safety of Tenecteplase in Patients With Late-Window Acute Ischemic Stroke and Evidence of Salvageable Tissue: Results From the Phase 3 Timeless Trial · 2023 | This clinician | $362 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1205889698
- Licence
- CA G55661California G55661: Current · expires 2027-03-31
- Trained
- University of California, San Diego School of Medicine, 1984
- Group
- Stanford Health Care
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2084V0102X (2084V0102X); Neurology (2084N0400X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-05-18
- NPI last updated
- 2023-11-09
- NPI record certified
- 2023-11-09
This is when the NPI record was last certified, not a medical board exam.